Skip to main
VIGL
VIGL logo

Vigil Neuroscience (VIGL) Stock Forecast & Price Target

Vigil Neuroscience (VIGL) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Vigil Neuroscience Inc. is positioned favorably due to its focus on developing therapeutics that target neurodegenerative diseases, specifically leveraging its VG-3927 drug, which exhibits a favorable safety and engagement profile supporting once-daily dosing. The company's ongoing studies have shown promising biomarker data, indicating a nearly 50% dose-dependent reduction in TREM2 levels in cerebrospinal fluid, which signals robust and sustained target engagement relevant for disease-modifying potential. As Vigil secures a comprehensive natural history package and integrates multiple biomarkers and imaging data into its studies, the resulting data set is expected to strengthen its case for regulatory approvals and drive future growth.

Bears say

Vigil Neuroscience has experienced a significant decline in its stock price following the ALEC TREM2 data readout, with shares dropping 26% and a reported net loss of $23.8 million, equating to a GAAP EPS of -$0.57 in 4Q24. The company's valuation outlook has also deteriorated, as indicated by an increase in the discount rate to 35%, leading to a target price reduction from $24 to $13, despite this target still being above current trading levels. The potential for commercial execution failures and the competitive landscape pose additional risks that could adversely affect the company’s performance and stock value.

Vigil Neuroscience (VIGL) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vigil Neuroscience (VIGL) Forecast

Analysts have given Vigil Neuroscience (VIGL) a Hold based on their latest research and market trends.

According to 3 analysts, Vigil Neuroscience (VIGL) has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vigil Neuroscience (VIGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.